Why most skin products don't work —
and what does.
90% of women are frustrated that skincare products don't deliver. The reason is structural. Most products treat the surface. The surface is not the problem.
Endogenic pharmacology · Khavinson research lineage 1971–2024 · US observational studies registered
The problem
Hope without mechanism doesn't work.
The average woman holds four products right now that didn't deliver what they promised. She has spent $170 this year alone on trial and error. She has stopped trusting the category.
The problem is not the ingredients. The problem is where they operate. Surface products address surface concerns. What her skin needs is addressed below the surface — at the cellular signaling level that daily skincare cannot reach.
Drive Research · Benchmarking Company · YouGov 2025
The science
Professor Vladimir Khavinson.
1971–2024.
Director, St. Petersburg Institute of Bioregulation and Gerontology · 775 published papers · 196 patents
What he discovered
Short-chain peptides (2–7 amino acids) cross cell membranes, enter the nucleus, and bind directly to DNA promoter sequences — activating tissue-specific gene expression that age depletes.
Six decades of research
Peer-reviewed, indexed, and validated across institutions in Russia, Europe, and the United States. The research lineage spans skin, tissue, collagen, and cellular signaling.
Where HelioMend fits
HelioMend, a division of Opticeuticals Inc., extends this lineage. We identified the compounds. We built protocols around them. We registered US observational studies to generate the evidence.
Our position
“We are not making claims.
We are in the process of proving them.”
HelioMend · Opticeuticals Inc. · Observational studies registered on ClinicalTrials.gov · Patent portfolio pending
The compounds
Endogenic pharmacology.
The science of healing from within.
Each protocol in the HelioMend Khavinson Collection is built around a compound class with published research behind it. The compound targets the mechanism. The mechanism addresses the concern.
Browse the Khavinson research archive →GHK-Cu Complex
Collagen synthesis · dermal density · fibroblast signaling
PDRN + Fibronectin
A2A receptor activation · barrier repair cascade
Oligopeptide Complex
Keratinocyte proliferation · surface renewal
EGF Oligopeptide
Basal layer renewal · texture restoration
Copper Peptide Complex
Follicular support · angiogenesis · scalp microenvironment
Fibronectin + HA
Extracellular matrix support · barrier hydration
Collagen Peptide
Vermilion border collagen density · lip tissue structure
The evidence
US observational studies. Registered. Running.
We identified compounds with six decades of published research behind them. We built protocols around those compounds. We registered observational studies with ClinicalTrials.gov to generate US clinical data on them.
GHK-Cu Skin Outcomes Registry
Observational · Non-IND · ClinicalTrials.gov
PDRN Barrier Function Registry
Observational · Non-IND · ClinicalTrials.gov
BPC-157 Tissue Repair Registry
Observational · Non-IND · ClinicalTrials.gov
These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease. Studies are observational registries — no investigational drug is assigned.
In recognition of Professor Vladimir Khavinson's six decades of bioregulator research.
1971–2024 · HelioMend · A division of Opticeuticals Inc.